Literature DB >> 19433476

An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide.

Geoffrey D Wool1, Tomas Vaisar, Catherine A Reardon, Godfrey S Getz.   

Abstract

Modifying apolipoprotein (apo) A-I mimetic peptides to include a proline-punctuated alpha-helical repeat increases their anti-inflammatory properties as well as allows better mimicry of full-length apoA-I function. This study compares the following mimetics, either acetylated or biotinylated (b): 4F (18mer) and 4F-proline-4F (37mer, Pro). b4F interacts with both mouse HDL (moHDL) and LDL in vitro. b4F in vivo plasma clearance kinetics are not affected by mouse HDL level. Administration of biotinylated peptides to mice demonstrates that b4F does not associate with lipoproteins smaller than LDL in vivo, though it does associate with fractions containing free hemoglobin (Hb). In contrast, bPro specifically interacts with HDL. b4F and bPro show opposite binding responses to HDL by surface plasmon resonance. Administration of acetylated Pro to apoE(-/-) mice significantly decreases plasma serum amyloid A levels, while acetylated 4F does not have this ability. In contrast to previous reports that inferred that 4F associates with HDL in vivo, we systematically examined this potential interaction and demonstrated that b4F does not interact with HDL in vivo but rather elutes with Hb-containing plasma fractions. bPro, however, specifically binds to moHDL in vivo. In addition, the number of amphipathic alpha-helices and their linker influences the anti-inflammatory effects of apoA-I mimetic peptides in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19433476      PMCID: PMC2724789          DOI: 10.1194/jlr.M900151-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  27 in total

1.  Markers for low-density lipoprotein oxidation.

Authors:  M Aviram; J Vaya
Journal:  Methods Enzymol       Date:  2001       Impact factor: 1.600

2.  Metabolism of apoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits.

Authors:  Patrick Kee; Kerry-Anne Rye; John L Taylor; P Hugh R Barrett; Philip J Barter
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-11-01       Impact factor: 8.311

3.  Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.

Authors:  Mohamad Navab; G M Anantharamaiah; Susan Hama; David W Garber; Manjula Chaddha; Greg Hough; Roger Lallone; Alan M Fogelman
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

4.  Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma.

Authors:  D Lapenna; G Ciofani; S D Pierdomenico; M A Giamberardino; F Cuccurullo
Journal:  Free Radic Biol Med       Date:  2001-08-01       Impact factor: 7.376

5.  A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis.

Authors:  D W Garber; G Datta; M Chaddha; M N Palgunachari; S Y Hama; M Navab; A M Fogelman; J P Segrest; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2001-04       Impact factor: 5.922

6.  Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice.

Authors:  C A Reardon; L Blachowicz; T White; V Cabana; Y Wang; J Lukens; J Bluestone; G S Getz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-06       Impact factor: 8.311

7.  Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.

Authors:  Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Susan Hama; Greg Hough; Victor R Grijalva; Alan C Wagner; Joy S Frank; Geeta Datta; David Garber; Alan M Fogelman
Journal:  Circulation       Date:  2004-06-14       Impact factor: 29.690

8.  Mining biomarkers in human sera using proteomic tools.

Authors:  Rulin Zhang; Lisa Barker; Deborah Pinchev; John Marshall; Michèle Rasamoelisolo; Chris Smith; Peter Kupchak; Inga Kireeva; Leslee Ingratta; George Jackowski
Journal:  Proteomics       Date:  2004-01       Impact factor: 3.984

9.  Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.

Authors:  Brian J Van Lenten; Alan C Wagner; Chun-Ling Jung; Piotr Ruchala; Alan J Waring; Robert I Lehrer; Andrew D Watson; Susan Hama; Mohamad Navab; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2008-07-11       Impact factor: 5.922

10.  Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response.

Authors:  Veneracion G Cabana; Catherine A Reardon; Ning Feng; Sean Neath; John Lukens; Godfrey S Getz
Journal:  J Lipid Res       Date:  2003-01-16       Impact factor: 5.922

View more
  24 in total

1.  Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.

Authors:  Wilissa D'Souza; John A Stonik; Andrew Murphy; Steven J Demosky; Amar A Sethi; Xiao L Moore; Jaye Chin-Dusting; Alan T Remaley; Dmitri Sviridov
Journal:  Circ Res       Date:  2010-05-27       Impact factor: 17.367

Review 2.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

3.  An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice.

Authors:  Shu-Chen Lu; Larissa Atangan; Ki Won Kim; Michelle M Chen; Renee Komorowski; Carolyn Chu; Joon Han; Sylvia Hu; Wei Gu; Murielle Véniant; Minghan Wang
Journal:  J Lipid Res       Date:  2012-01-27       Impact factor: 5.922

4.  4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice.

Authors:  Geoffrey D Wool; Veneracion G Cabana; John Lukens; Peter X Shaw; Christoph J Binder; Joseph L Witztum; Catherine A Reardon; Godfrey S Getz
Journal:  FASEB J       Date:  2010-09-27       Impact factor: 5.191

5.  Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides.

Authors:  Gaurav Nayyar; Vinod K Mishra; Shaila P Handattu; Mayakonda N Palgunachari; Ronald Shin; David T McPherson; Champion C S Deivanayagam; David W Garber; Jere P Segrest; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2012-02-29       Impact factor: 5.922

6.  5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.

Authors:  Marcelo J A Amar; Wilissa D'Souza; Scott Turner; Stephen Demosky; Denis Sviridov; John Stonik; Jayraz Luchoomun; Jason Voogt; Marc Hellerstein; Dmitri Sviridov; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2010-05-19       Impact factor: 4.030

7.  Mimetic peptides of human apoA-I helix 10 get together to lower lipids and ameliorate atherosclerosis: is the action in the gut?

Authors:  Geoffrey D Wool; Catherine A Reardon; Godfrey S Getz
Journal:  J Lipid Res       Date:  2014-08-01       Impact factor: 5.922

8.  Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux.

Authors:  David Meriwether; Dawoud Sulaiman; Alan Wagner; Victor Grijalva; Izumi Kaji; Kevin J Williams; Liqing Yu; Spencer Fogelman; Carmen Volpe; Steven J Bensinger; G M Anantharamaiah; Ishaiahu Shechter; Alan M Fogelman; Srinivasa T Reddy
Journal:  J Lipid Res       Date:  2016-05-19       Impact factor: 5.922

Review 9.  Structure and function of HDL mimetics.

Authors:  Mohamad Navab; Ishaiahu Shechter; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-16       Impact factor: 8.311

Review 10.  High-density lipoprotein mimetics: promises and challenges.

Authors:  Dmitri Sviridov; Alan T Remaley
Journal:  Biochem J       Date:  2015-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.